Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study.
imaging/CT MRI etc
primary pulmonary hypertension
Journal
Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
24
08
2020
revised:
20
01
2021
accepted:
08
02
2021
pubmed:
27
2
2021
medline:
18
1
2022
entrez:
26
2
2021
Statut:
ppublish
Résumé
End points that are repeatable and sensitive to change are important in pulmonary arterial hypertension (PAH) for clinical practice and trials of new therapies. In 42 patients with PAH, test-retest repeatability was assessed using the intraclass correlation coefficient and treatment effect size using Cohen's d statistic. Intraclass correlation coefficients demonstrated excellent repeatability for MRI, 6 min walk test and log to base 10 N-terminal pro-brain natriuretic peptide (log
Identifiants
pubmed: 33632769
pii: thoraxjnl-2020-216078
doi: 10.1136/thoraxjnl-2020-216078
pmc: PMC8461450
doi:
Substances chimiques
Peptide Fragments
0
Natriuretic Peptide, Brain
114471-18-0
Banques de données
ClinicalTrials.gov
['NCT03841344']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1032-1035Subventions
Organisme : Wellcome Trust
ID : 205188/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M008894/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 205188/Z/16/Z
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/14/6/31350
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206632/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: FW, LK and AC are employees and shareholders of GlaxoSmithKline. AS is the principal investigator for the collaborative research grant from GlaxoSmithKline that funded this study. AS has undertaken consultancy work for General Electric and Actelion Pharmaceuticals. RC has received fees for lecturing and participation in advisory boards, from Actelion, Bayer, GSK and MSD. DGK has received fees for lecturing and participation in advisory boards, from Actelion, Bayer, GSK and MSD and fees for participation in Steering Committees for Actelion.
Références
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Am J Respir Crit Care Med. 2017 Jul 15;196(2):228-239
pubmed: 28328237
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545975
Eur Respir J. 2012 Apr;39(4):945-55
pubmed: 21885399
Front Psychol. 2013 Nov 26;4:863
pubmed: 24324449
J Am Coll Cardiol. 2011 Dec 6;58(24):2511-9
pubmed: 22133851
Am Heart J. 2004 Feb;147(2):218-23
pubmed: 14760316
Pulm Circ. 2019 Mar 18;:2045894019841990
pubmed: 30880632
Am J Respir Crit Care Med. 2020 Feb 15;201(4):458-468
pubmed: 31647310
JACC Cardiovasc Imaging. 2021 May;14(5):931-942
pubmed: 33008758